ENDPOINTS

J&J touts new survival data for lung cancer combo

Johnson & Johnson released new data suggesting its lung cancer combination Rybrevant and Lazcluze beat AstraZeneca’s Tagrisso on overall survival. In a Phase 3 trial, 56% of patients who took J&J’s combination treatment were alive ...

Mar 26, 2025 - 17:04
 0
J&J touts new survival data for lung cancer combo
Johnson & Johnson released new data suggesting its lung cancer combination Rybrevant and Lazcluze beat AstraZeneca’s Tagrisso on overall survival. In a Phase 3 trial, 56% of patients who took J&J’s combination treatment were alive ...
Read More

Tags:

Previous Article

NASA Starling and SpaceX Starlink Improve Space Traffic Coordination

Next Article

Imaging Volumes Are Exploding. AI May Be the Only Way to Keep Up

Related Posts

Genentech's TNKase gets new approval; Sanofi gives up rights to oncology candidate

Genentech's TNKase gets new approval; Sanofi gives up r...

Mar 3, 2025  0

ACIP meeting, delayed earlier this year, is rescheduled

ACIP meeting, delayed earlier this year, is rescheduled

Mar 20, 2025  0

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

After Phase 3 depression setback, Neumora pauses two tr...

Mar 3, 2025  0